

## References

I-26

1. American Urological Association. Castration-resistant prostate cancer: AUA guideline. Accessed 11/19/2015.
2. Pieconka C, Telonis D, Mouraviev V, et al. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: Considerations for clinical practice. *Rev* 2015;17(4):203–210.
3. Scholz M, Yep S, Chancey M, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. 2017;11-16.
4. Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. *Core Evidence*. 2015;1-10.
5. Yi R, Chen B, Duan P, et al. Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. *Jour Immun Reasearch*. 2016:1-10.
6. MICROMEDEX®SOLUTIONS Compendia.2020. Sipuleucel-T.
7. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Sipuleucel- 2020.
8. Mulders P, Santis M, Powles T, Fizazi K. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. *Cancer Immunology, Immunotherapy*. 2015;64(6):655-663.
9. Provenge (sipuleucel-T) suspension for intravenous infusion [package insert]. Dendreon Pharmaceuticals, LLC. Seal Beach, CA. Revised 07/2017.
10. National Comprehensive Cancer Network (NCCN). Sipuleucel-T. NCCN Drugs and Biologics Compendium®. 2020.